ArticleVirology journal2024

Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.

Samuel M S Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.